. Inventory days were 79 days as at 30th June, 2017 and 78 days as at 30th June, 2016. Liquidity Liquidity ratios are high at approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in
30th September, 2017 and 71 days as at 30th September, 2016. Liquidity Liquidity ratios are high at approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q3 2017 was THB
%). This promising growth was due to more subspecialties as well as capacity expansion. OPD increased by 3 units and IPD increased by 17 units yoy. Number of OPD patients remained on the rise while revenue
were 96 days as at 31st March, 2019 and 80 days as at 31st March, 2018 . Liquidity Liquidity ratios are high at approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q1 2019
high at approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q2 2019 was THB 696m which was 9% lower than Q2 2018 was THB 765m. Capital Expenditure Net Capital Expenditure
March, 2017. Liquidity Liquidity ratios are high at approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q1 2018 was THB 609m which was 30% lower than Q1 2017 at THB 873m
. Liquidity Liquidity ratios are high at approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q2 2018 was THB 766m which was 4% lower than Q2 2017 was THB 801m. Capital
high at approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q3 2019 was THB 664m which was 40% lower than Q3 2018 was THB 1,098m. Capital Expenditure Net Capital
approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q1 2020 was THB 766m which was 68% higher than Q1 2019 was THB 455m. Capital Expenditure Net Capital Expenditure was THB 230m in
26.9% TKS 285 326 (12.5)% TBSP 33 0.5 7,182% Non-recurring profit* 92 - 100% Non-recurring profit** - 213 (100)% Non-recurring loss A) - (212) 100% Non-recurring loss B) - (24) 100% Net profit for 2019